Celltrion Expands Japan Autoimmune Portfolio With Steqeyma IV Launch
Celltrion has launched the intravenous formulation of its ustekinumab biosimilar Steqeyma in Japan, expanding an autoimmune disease portfolio that already includes market-leading biosimilars Remsima and Yuflyma.The launch represents more than the addition of another product to Celltrion's Japane
Celltrion has launched Steqeyma IV, an intravenous formulation of its ustekinumab biosimilar, in Japan, broadening its autoimmune disease portfolio alongside Remsima and Yuflyma. This move leverages Japan's substantial pharmaceutical market and Celltrion's established commercial infrastructure and physician networks to bolster its product lineup.
Established with Remsima (46.9% share) and Yuflyma (19.5% share), Celltrion plans to use these relationships to fast-track Steqeyma's adoption. Offering both IV and subcutaneous formulations, Steqeyma provides physicians greater flexibility, particularly for Crohn's disease, where IV formulation is ideal for induction therapy, transitioning to SC for maintenance.
Celltrion's strategy also includes other autoimmune products like Remsima SC, scheduled for a 2024 Japanese launch. The company's approach reflects a growing trend in biosimilar competition—building a portfolio of products to serve overlapping medical specialties and hospital networks, enhancing sales efficiency and provider relationships.
With Japan's aging population and healthcare expenditure challenges, Celltrion's portfolio strategy could accelerate the adoption of biosimilar treatments, positioning Steqeyma as a key player in Japan's autoimmune disease market.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
